Toprol OK's a boon for Watson amid shortage

Watson Pharmaceuticals could reap big benefits from the approval of its version of the blood pressure med Toprol XL, because two rival generic drugs were suspended because of manufacturing problems. "We get these opportunities every once in a while and this is one of those unique opportunities," Watson spokeswoman Patty Eisenhaur told Reuters, referring to the sudden recent disappearance from the U.S. market of the rival Novartis and KV Pharmaceutical generics. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.